Jude Canon investigated the KRAS G12C inhibitor AMG510 in chemical and biological systems. The study connected inhibition of an oncogenic signaling protein with changes in tumour–immune interactions in the experimental models.[ref]
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity by Jude Canon and others. 2019, abstract and experimental tumour-immunity observations; historical research result, not treatment guidance
Articles by others on the same topic
There are currently no matching articles.